Stockwinners Market Radar for November 05, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:28 EDT Gol Linhas reports preliminary October traffic up 13.9% - In the domestic market, demand for GOL's flights increased 13.9% and supply increased by 5.3%. GOL's domestic load factor was 84.3% in October, a 6,4 p.p higher in comparison to October 2020. GOL transported 1.9M passengers during the month, a 23.5% increase over October 2020. GOL did not operate regular international flights during the month.

17:14 EDT Khosla Ventures Acquisition Co. II, Nextdoor complete take-public transaction - Nextdoor (KIND) and Khosla Ventures Acquisition Co. II (KVSB), a special purpose acquisition company, have completed their previously announced transaction to take Nextdoor public. The combined company is expected to start trading on The New York Stock Exchange on November 8, 2021 under the new ticker symbol "KIND" for Nextdoor Class A common stock. "We are thrilled to have completed our combination with KSVB and to be listing on the NYSE under the ticker "KIND". Through the KVSB trust proceeds and the fully committed private placement, we raised $674 million that will help us to fund long-term growth at scale and enable our purpose of cultivating a kinder world where everyone has a neighborhood to rely on," said Nextdoor CEO Sarah Friar. "We chose "KIND" as our NYSE ticker as kindness is core to Nextdoor's purpose. At Nextdoor, we want to give neighbors ways to connect and be kind to each other, online and in real life. We believe a little kindness goes a long way towards making life easier, neighborhoods stronger, and the world a better place."

16:55 EDT Astra applies with FCC to launch, operate satellite system - In a regulatory filing, Astra disclosed it filed an application with the Federal Communication Commission, under which it requested authority to launch and operate a non-geostationary orbit satellite system using V-band frequencies. Assuming Astra is approved for a license, the Constellation would be part of the "Satellite Services" line of its business, which the company has described as ranging "from operational support of satellites on orbit, to turnkey provision of entire constellations." Astra recognizes that its choice to refer this line of business as "Satellite Services" may lead investors and others to misunderstand the scope of this service offering. Thus, Astra will now refer to this line of business as "Space Services" and to clarify it encompasses all aspects of hosted satellite and constellation services, including hosting customer payloads onto its satellites, and delivering services, such as communication and other services, to customers from its space platform.

16:26 EDT Meridian Bancorp, Independent Bank receive all regulatory approvals for deal - Independent Bank Corp. (INDB), parent of Rockland Trust Company, and Meridian Bancorp (EBSB), parent of East Boston Savings Bank, jointly reported the following in connection with Independent's proposed acquisition of Meridian: All regulatory approvals relating to the transaction have now been received. The transaction is expected to be completed on November 12, 2021, subject to the satisfaction of the remaining customary closing conditions.

16:20 EDT Trinseo exploring divestiture of styrenics businesses, to launch sales process - Trinseo has begun work to explore the divestiture of its styrenics businesses and plans to launch a formal sales process in Q1 of 2022. The scope of this potential divestiture is expected to include the Feedstocks and Polystyrene reporting segments as well as the company's 50% ownership of Americas Styrenics. Bozich stated "The separation of the styrenics businesses would represent another key step in our transformation toward becoming a specialty materials and sustainable solutions provider. We will continue to prioritize investments in higher growth, higher margin and lower earnings volatility areas such as Engineered Materials and CASE with an ongoing focus on sustainability, including the continued decrease in our CO2 intensity through various initiatives including the transformation of our portfolio."

16:13 EDT Havertys announces special cash dividend, new $25M share repurchase plan - Havertys announced that its board of directors authorized a special cash dividend to be paid on the outstanding shares of the two classes of $1 par value common stock of the company at a rate of $2.00 per share on the common stock and $1.90 per share on the Class A common stock. The board also approved the payment of the quarterly cash dividend of 25c per share on the common stock and 23c per share on the Class A common stock. The special cash dividend and regular quarterly dividend will be paid together on December 8 to stockholders of record at the close of business on November 22. The board also approved a new authorization under its stock repurchase program that permits the company to purchase up to $25M of its common stock and Class A common stock once the approximately $22.3M remaining authorization is utilized.

16:06 EDT ACRES Commercial Realty Corp. reauthorizes $20M share repurchase plan - ACRES Commercial Realty Corp. announced that its board of directors authorized and approved the continued use of its existing share repurchase program, originally authorized by the Board in March 2016, in order to repurchase up to $20M of the currently outstanding shares of its common stock.

16:02 EDT Amgen starts construction on new biomanufacturing plant in Ohio - Amgen announced the groundbreaking of its newest biomanufacturing plant, located in New Albany, Ohio. The final product assembly and packaging plant will support the growing demand for Amgen's medicines in the United States and is expected to be operational by 2024. "In building this site, we expect to invest $365 million," said Sam Guhan, vice president of Engineering at Amgen. "Environmental sustainability will be a priority, and we aspire for this plant to be LEED-certified and designed. We will maximize energy efficiency and waste reduction, advancing Amgen's plan to make our operations carbon neutral over the next several years."

16:00 EDT Omeros announces long-term results from narsoplimab trial - Omeros announced results of long-term follow-up from the Phase 2 clinical trial evaluating its MASP-2 inhibitor narsoplimab in patients with IgA nephropathy. Treatment with narsoplimab in this trial was associated with an unprecedented median reduction in proteinuria of 64.4%. Now, long-term follow-up of these patients shows a markedly slowed rate of decline of estimated glomerular filtration rate, or eGFR. Using the same analytical approach adopted by other companies to determine the impact of proteinuria reduction on long-term risk of need for dialysis, a 64.4 percent reduction in proteinuria is predicted to delay progression to renal dialysis by 41.6 years compared to standard of care. While other companies have reported up to 1-year follow-up data on eGFR, this is the first time that sustained stabilization, let alone improvement, of eGFR through long-term follow-up has been reported for any novel therapeutic in development for IgA nephropathy. ARTEMIS-IGAN, the Phase 3 clinical trial of narsoplimab in IgA nephropathy, is ongoing. The Phase 2 clinical trial consisted of two sequential studies. Substudy 1 was a single-arm, open-label design with 12 weekly intravenous, or IV, infusions of narsoplimab in patients who, at time of enrollment, were on corticosteroids that were tapered during the study; the four IgA nephropathy patients from substudy 1 were able to enter a dosing extension period. In substudy 2, which included nine evaluable patients, corticosteroid-free patients were randomized 1:1 to receive once-weekly IV narsoplimab or vehicle infusions for 12 weeks, after which they could continue in an open-label extension at the investigator's discretion. A total of 12 patients participated in the dosing extension phase. These 12 patients were followed for up to nearly three years, with the last assessment at 19 months or later for 75% of the study patients and at two years or later for 50% of them. The narsoplimab trial population consisted of high-risk patients with advanced IgA nephropathy at study baseline with a median disease duration of 6.9 years. Several other risk factors, such as hypertension and obesity were present in a large majority of the cases along with excessive baseline proteinuria and renal failure. Narsoplimab appeared effective irrespective of the stage of the study patients' advanced disease state and, using the same analytical approach adopted by other companies, is predicted to provide an unprecedented delay in progression to renal dialysis. A median reduction in proteinuria of 64.4 percent was previously observed across the 2 substudies in the narsoplimab Phase 2 trial. The magnitude of median proteinuria reduction seen with narsoplimab is predicted to delay progression to renal dialysis by 41.6 years compared to standard of care. Through the nearly three-year extended follow-up: Study patients received a median of one course of 12 weekly doses of narsoplimab per year, with 58% of patients receiving one course or less per year. eGFR rate of decline was slowed by 3.4 mL/min/year compared to a literature control cohort with IgA nephropathy matched for proteinuria excretion and eGFR levels. eGFR showed improvement in 25 percent of the patients despite having significant IgA nephropathy with sclerotic lesions present in the glomeruli and with significant risk factors such as longstanding disease up to 18 years, obesity with BMI up to 38.1kg/m2, and long history of hypertension. Narsoplimab was well tolerated with no treatment-related serious adverse events.

15:37 EDT P.A.M. Transportation reauthorizes 500,000 share repurchase program - P.A.M. Transportation announced that its Board of Directors has approved, effective immediately, a reauthorization to repurchase up to 500,000 shares of the company's common stock. The company's stock repurchase program has been extended and expanded several times since the original authorization in 2011, and this reauthorization acts as a replenishment of shares under the repurchase program.

15:07 EDT Eli Lilly says Jardiance reduced cardiovascular death in Phase III study - Eli Lilly announced that Jardiance reduced the risk for the composite primary endpoint of cardiovascular death or hospitalization for heart failure and slowed kidney function decline in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status at baseline, according to findings from a new prespecified sub-analysis of the EMPEROR-Preserved Phase III trial. In EMPEROR-Preserved, two thirds of enrolled adults had heart failure with preserved ejection fraction and one third had mildly reduced left ventricular ejection fraction. The results were presented at the American Society of Nephrology Kidney Week 2021. 53.5% of adults in EMPEROR-Preserved had chronic kidney disease at trial entry, and 9.7% had severe kidney impairment. The new prespecified sub-analysis of EMPEROR-Preserved demonstrated that the benefits seen in the overall population were consistent in adults with and without chronic kidney disease, Lilly said. Jardiance consistently improved cardiovascular outcomes and slowed kidney function decline across the full range of kidney function down to an eGFR of 20 mL/min/1.73 m, it added.

14:06 EDT Entravision acquires digital advertising solutions company 365 Digital - Entravision (announced that it has acquired 365 Digital, a digital advertising solutions company headquartered in South Africa. "This investment provides Entravision with a geographic foothold in Africa, as the Company looks to expand its breadth of digital services to new emerging markets. Headquartered in Cape Town, South Africa, 365 Digital maintains exclusive sales representations with TikTok, the leading destination for short-form mobile video and brand solutions, and Anzu, an in-game advertising platform, and is also the authorized representative for Triton Digital, a leader in the digital audio streaming and podcasting market. 365 Digital also offers end-to-end digital publisher solutions for premier South African publishers, including a proprietary digital ad network," the company said. Upon the closing of this transaction, all 365 Digital employees will remain with the company and Julian Jordaan will continue to serve as CEO of the business based out of its headquarters in Cape Town.

13:40 EDT GSK announces 'positive' Phase 3 efficacy and safety data for daprodustat in CKD - GlaxoSmithKline announced "positive" results from the Phase 3 ASCEND program for daprodustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, during a presentation at the American Society of Nephrology's Kidney Week 2021. "The positive primary efficacy and safety results confirm the potential for daprodustat to be a new oral treatment for patients with anemia due to chronic kidney disease, or CKD, in both non-dialysis and dialysis settings," the company said. The ASCEND-ND and ASCEND-D studies each independently met their primary efficacy and safety endpoints. Efficacy results from both Phase III studies demonstrated that daprodustat improved or maintained patients within their target hemoglobin range. In addition, results from the prespecified primary safety analysis of the intention-to-treat population showed similar rates of major adverse cardiovascular events, or MACE, defined as all-cause mortality, non-fatal myocardial infarction, or non-fatal stroke independently within each trial. In the ASCEND-ND trial, results showed a hazard ratio reflecting time to first occurrence of MACE of 1.03, achieving non-inferiority with the pre-defined margin of 1.25. In the ASCEND-D trial, results showed a hazard ratio reflecting time to first occurrence of MACE of 0.93, achieving non-inferiority with the pre-defined margin of 1.25. The outcomes in each study and across treatment arms confirmed no increased cardiovascular risk for daprodustat compared to an erythropoietin stimulating agent, the current standard of care. The most commonly reported adverse events in patients receiving daprodustat included hypertension, diarrhea, dialysis hypotension, peripheral edema and urinary tract infection. "Daprodustat is the first oral HIF-PHI to clearly show positive efficacy, along with no increased cardiovascular risk as assessed in the primary analysis of MACE in the ITT population compared to an ESA, across both non-dialysis patients and dialysis patients," the company said.

13:26 EDT Entain reports BetMGM launches first retail sportsbook in Arizona - BetMGM and Gila River Hotels & Casinos announced the opening of The BetMGM Sportsbook at Vee Quiva. "This marks the first opening of a BetMGM retail sportsbook in Arizona and Phoenix's first in-casino sportsbook," said Entain (GMVHF), one of the two co-owners of the BetMGM joint venture. In August, BetMGM, jointly owned by Entain and MGM Resorts International (MGM), announced partnerships with Gila River Hotels & Casinos and the Arizona Cardinals for retail and online sports betting, Entain noted. Reference Link

13:03 EDT Baker Hughes reports U.S. rig count up 6 to 550 rigs - Baker Hughes reports that the U.S. rig count is up 6 from last week to 550 with oil rigs up 6 to 450, gas rigs unchanged at 100, and miscellaneous rigs unchanged at 0. The U.S. Rig Count is up 250 rigs from last year's count of 300, with oil rigs up 224 gas rigs up 29 and miscellaneous rigs down 3. The U.S. Offshore Rig Count is unchanged at 13, up 1 year-over-year. The Canada Rig Count is down 6 from last week to 160, with oil rigs down 3 to 95, gas rigs down 3 to 65. The Canada Rig Count is up 74 rigs from last year's count of 86, with oil rigs up 58, gas rigs up 16.

12:40 EDT Endo off highs after adding bankruptcy risk to quarterly filing - Shares of Endo International are off the day's highs, but remain up 23% to $6.10, after the company included the risk of bankruptcy in its Q3 quarterly filing. In its Q2 filing, Endo said it is possible that its legal proceedings, including those relating to opioid claims, "could have a material adverse effect on our business." However, in today's filing for Q3, the company added that the implications of the legal proceedings "could result in a possible restructuring of our or our subsidiaries' obligations through a bankruptcy filing which, if it were to occur, would subject us to additional risks and uncertainties that could adversely affect our business prospects and ability to continue as a going concern."

12:21 EDT KLA Corp. officially opens $200M second headquarters in Ann Arbor, Michigan - KLA Corporation announced the official opening of its second U.S. headquarters, a $200M facility in Ann Arbor, Michigan. Following its 2018 announcement to invest and break ground in Ann Arbor, KLA opens its new campus with a locally-based leadership team and more than 300 employees, with plans for an additional 300 hires over the next 12 to 18 months. "With the opening of its new facility, KLA is helping us build Michigan's future," said Michigan Governor Gretchen Whitmer. "The next generation of technology and innovation are happening right here in Ann Arbor, thanks to KLA and partners including the Michigan Economic Development Committee and University of Michigan. With KLA's bold investment and commitment to the community, we'll continue growing Michigan's economy, creating good-paying jobs, and securing our position on the world's high-tech stage. Together, we will usher in a new era of prosperity for our families and communities."

12:09 EDT Bed Bath & Beyond rallies 3% after Citron puts $50-$70 target on shares

12:00 EDT SelectQuote falls -18.9% - SelectQuote is down -18.9%, or -$2.47 to $10.61.

12:00 EDT Revlon rises 18.4% - Revlon is up 18.4%, or $2.18 to $14.05.

12:00 EDT Shake Shack rises 22.8% - Shake Shack is up 22.8%, or $17.77 to $95.85.

11:24 EDT Shell Oil Company acquires MSTS Payments - Shell Oil Company, an affiliate of the Royal Dutch Shell plc, has acquired MSTS Payments and its Multi Service Fuel Card business from Multi Service Technology Solutions, dba TreviPay. "The Multi Service Fuel Card acceptance network and transaction processing platform provides Shell with a closed-loop payment network used by Commercial Road Transport companies at thousands of truck stops in North America... The investment in the Multi Service Fuel Card business includes growing market share in the fuel card space and creating synergies with Shell product offerings. Shell plans to add services to enhance the customer experience and leverage its heavy duty diesel engine oil brand, Shell Rotella, to offer trucking fleets fuel-economy savings, extended-drain capability, enhanced engine cleanliness, and excellent wear protection," the company said.

11:03 EDT Medtronic reports five-year clinical data from SURTAVI trial - Medtronic announced five-year clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation, or SURTAVI, trial, which was presented as a Late Breaking Clinical Trial at the 33rd Transcatheter Cardiovascular Therapeutics, or TCT, conference, the annual scientific symposium of the Cardiovascular Research Foundation. Data from the trial showed that the hemodynamic benefits of the Medtronic CoreValve and Evolut platforms were maintained at five years with "an excellent safety profile and stable valve performance" in patients with symptomatic, severe aortic stenosis who are at an intermediate risk for open-heart surgery, the company said. At five years, rates of all-cause mortality were similar between TAVR with the CoreValve/Evolut platform and surgical aortic valve replacement, or SAVR, with 30.0% for TAVR versus 28.7% for SAVR, while rates of disabling stroke were also similar with 4.1% for TAVR versus 5.8% for SAVR. The TAVR arm continued to demonstrate durable valve longevity, as evidenced by better mean aortic valve gradients at five years. Additionally, valve thrombosis remained low out to five years for both TAVR and SAVR, the company said.

10:48 EDT Nintendo to open Nintendo Store in Osaka - Nintendo said it is opening another Nintendo Store in Japan, this time in Osaka. Nintendo Osaka will open at the end of 2022 and will be the second directly managed official shop, joining Nintendo Tokyo. Reference Link

10:10 EDT AbbVie presents data from two Phase 3 trials on risankizumab at ACR meeting - AbbVie announced the presentation of integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, evaluating the efficacy and safety of risankizumab, or Skyrizi, in adult patients with active psoriatic arthritis, or PsA. The data showed that 24-weeks of treatment with risankizumab resulted in greater improvements in PsA signs and symptoms compared with placebo with no new safety signals, the company said. Patients receiving risankizumab achieved higher rates of ACR20 - 55.5% - than patients receiving placebo - 31.3% - at week 24. Additionally, patients receiving risankizumab showed greater improvements in the key clinical and patient-reported outcome endpoints compared to patients receiving placebo. These results will be featured in an American College of Rheumatology, or ACR, Convergence 2021 plenary session on Saturday, Nov. 6.

10:01 EDT Proto Labs CFO John Way resigns, Dan Schumacher named Interim CFO - Protolabs announced John Way is resigning as CFO to pursue an opportunity at another company. Way will continue in his role through November 30. Dan Schumacher, Vice President of Investor Relations and FP&A, has been named Interim CFO effective December 1. Schumacher has been with Protolabs for four years leading the company's investor relations and FP&A organizations, and has reported directly to Way since he joined the company in 2017. Schumacher will continue to work closely with Way and Rob Bodor, Protolabs' President and CEO, over the next month to ensure a smooth transition.

10:00 EDT SelectQuote falls -18.9% - SelectQuote is down -18.9%, or -$2.47 to $10.61.

10:00 EDT Canada Goose rises 14.4% - Canada Goose is up 14.4%, or $5.83 to $46.26.

10:00 EDT Shake Shack rises 17.4% - Shake Shack is up 17.4%, or $13.61 to $91.69.

09:47 EDT SelectQuote falls -13.9% - SelectQuote is down -13.9%, or -$1.82 to $11.26.

09:47 EDT Monmouth Real Estate rises 11.6% - Monmouth Real Estate is up 11.6%, or $2.18 to $21.04.

09:47 EDT Bill.com rises 14.4% - Bill.com is up 14.4%, or $42.31 to $336.21.

09:42 EDT Simplicity Esports signs agreement with Certified Guaranty Company - Simplicity Esports and Gaming (WINR) announced that 29 of its esports gaming centers have been designated as Official Submission Centers with CGC. The agreement makes Simplicity the largest network of Official Submission Centers in the CGC ecosystem. Roman Franklin, CEO of Simplicity Esports, stated, "I am thrilled to begin this partnership with the preeminent pop culture collectibles grading service in the world. We hold numerous TCG events per month across our footprint of esports gaming centers and sell Pokemon and Magic: The Gathering cards on-site to walk in customers and players in these tournaments, as well as collectors online via our newly launched e-commerce site SimplicityGames.com." CGC is a division of Certified Collectibles Group, which was recently acquired by Blackstone (BX).

09:28 EDT Shell Midstream announces Mars Oil Pipeline has resumed normal operations - Shell Midstream Partners and Shell Pipeline announced that they have re-started the West Delta-143 "A" offshore facilities. With the WD-143 "A" facilities now operational, the Mars Oil Pipeline Company has resumed normal operations as producers ramp up production.

09:11 EDT Groupon sees global billings moderately up in Q4 vs. Q3

09:08 EDT Ford announces launch of Ford Pro pilot program for all-electric E-Transit vans - The 2022 Ford E-Transit van, the all-electric version of the Ford Transit, is "getting to work early" through a Ford Pro pilot program, Ford announced. Companies nationwide, such as Penske Truck Leasing and National Grid, have taken delivery of preproduction units of the E-Transit van "with plans to use early learnings that will help deployment into their operations when the vehicle arrives to market early next year," Ford stated in a press release. Reference Link

09:06 EDT Ocular Therapeutix announces update from CMS for reimbursement of Dextenza - Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services, or CMS, released its final rules for the Outpatient Prospective Payment System, or OPPS, and Medicare Physician Fee Schedule, or MPFS, for 2022. The OPPS final rule confirms that Dextenza will continue to be separately paid by Medicare in the hospital outpatient department, or HOPD, and ambulatory surgical center, or ASC, settings for 2022. CMS further indicated that Dextenza is eligible to receive separate payment in the ASC setting because it meets the criteria set forth in the non-opioid as a surgical supply provision, which is favorable for 2023 and beyond.

09:02 EDT CubeSmart publishes inaugural sustainability report - CubeSmart issued its inaugural 2020 Sustainability Report. "I am proud that today we have published our inaugural Sustainability Report, reflecting the various initiatives we have undertaken to ensure CubeSmart is built for the long-term," said Christopher P. Marr, President and Chief Executive Officer of CubeSmart. "We look forward to using this report to share our progress along our stated goals in the coming years." Highlights from the 2020 report include: Introduced specific targets for sustainability goals across environmental, social, and governance initiatives; reductions in energy and GHG consumption and an increase in renewable energy generation in 2021; rnacted our Code of Ethics, Conduct & Human Rights for Vendors and Suppliers to encourage sustainable behavior throughout our supply chain.

08:37 EDT Bit Brother Limited regains compliance with Nasdaq minimum bid price requirement - Bit Brother Limited has regained compliance with Nasdaq's minimum bid price requirement. On November 3, the company received a written notification from Nasdaq indicating that the company has regained compliance with the minimum bid price requirement for continued listing on Nasdaq ) based on the company's closing bid price being $1.00 per share or greater for 10 consecutive business days from October 20 to November 2.

08:35 EDT Leo Holdings III Corp., Local Bounti announce upsizing of PIPE by $25M - Local Bounti and Leo Holdings III Corp announced they have entered into subscription agreements for an additional $25M of common stock in a private placement from new and existing PIPE investors on the same terms as the initial PIPE financing in the previously announced business combination transaction between Local Bounti and Leo on June 18. This increases the aggregate amount of expected PIPE proceeds to $150M. Commitments for the upsized PIPE come from new and existing PIPE investors, including Fidelity Management & Research Company LLC, BNP Paribas Asset Management Ecosystem Restoration Fund, strategic partner Sarath Ratanavadi, CEO of Gulf Energy Development Public Company Limited, Scott McNealy, co-founder and former CEO of Sun Microsystems, and affiliates of Leo's sponsor. With this increase in the fully committed PIPE, the $150M of expected PIPE proceeds will satisfy the minimum cash requirement for the Business Combination to close, as stipulated in the merger agreement entered into on June 18 by Local Bounti and Leo, regardless of any potential redemptions by Leo shareholders that may occur. As a result, and subject to Leo's shareholder approval and other customary closing conditions, Local Bounti and Leo expect to close the Business Combination as planned, resulting in Local Bounti becoming a publicly traded company.

08:33 EDT Omeros presents narsoplimab report at ASN - Omeros announced that the first report describing the effects of lectin-pathway inhibition by narsoplimab on urinary complement levels in kidney disease was presented yesterday at the Annual Meeting of the American Society of Nephrology, or ASN. The patient, a 21-year-old woman, presented with a rapidly progressive glomerulonephritis. The objective was to stabilize her rapidly deteriorating kidney function to allow for renal transplantation. Her clinical course and response to the MASP-2 inhibitor narsoplimab are detailed in a publication by Selvaskandan et al.1 In brief, kidney biopsy revealed marked vascular damage with significant interstitial fibrosis, tubular atrophy and evidence of complement involvement. Diagnosed with IgA vasculitis, she developed rapidly worsening kidney function with highly elevated creatinine levels, hypertension, proteinuria, and hematuria despite treatment with systemic corticosteroids. She began treatment with narsoplimab. After one course of 12 weekly doses of narsoplimab, her kidney function stabilized and she was able to undergo successful renal transplantation without the need for dialysis. As reported in yesterday's ASN Annual Meeting presentation, complement levels assessed in urinary samples collected during the patient's clinical course demonstrated substantial reduction in local complement activation associated with narsoplimab treatment-related lectin-pathway inhibition and stabilization of kidney function. Specifically, C4c/creatinine ratio, ficolin-3/creatinine ratio and C3bc/creatinine ratio levels were decreased 75%, 58% and 29%, respectively, from baseline to the end of the treatment. Levels of MBL and CL-11 remained stable during treatment. Further studies are ongoing to evaluate the use of urine as a non-invasive and readily accessible resource to monitor responses to narsoplimab treatment.

08:14 EDT OptimizeRx published analyst of multiple sclerosis - OptimizeRx published an analysis of multiple sclerosis, MS, research addressing the challenges and common causes of treatment delays and discontinuation in patients with MS, in particular noting the benefits of early MS treatment initiation in slowing disease progression and reducing areas of new damage in the brain and spinal cord. "With the increase in the adoption of technology solutions across healthcare, MS therapy manufacturers can support HCPs by leveraging real-world data in new ways at the point-of-care. The application of AI-driven predictive analytics to real-world evidence can support earlier diagnosis by connecting otherwise disparate critical patient data points in real-time. This application extends further to tailor digital patient support programs that can provide personalized educational resources throughout treatment and streamline access to financial assistance, which in turn can increase awareness and accessibility to help avoid treatment delays and abandonment," the company said.

08:14 EDT Ametek names Emanuela Speranza as Chief Commercial Officer - Ametek named Emanuela Speranza as Chief Commercial Officer and a member of the company's Executive Office, effective January 1, 2022. Speranza joined Ametek in 2014 as Vice President and General Manager, Ametek Precision Instruments, Europe, and most recently served as Vice President, International, where she oversaw Ametek's infrastructure in Europe and Asia. Prior to joining Ametek, Speranza held roles of increasing responsibility at Danaher.

08:09 EDT Cheniere Energy subsidiary enters into LNG SPA with Sinochem - Cheniere Energy (LNG) announced that its subsidiary, Cheniere Marketing, has entered into a binding liquefied natural gas, or LNG, sale and purchase agreement, or SPA, with Sinochem. Under the SPA, Sinochem Group has agreed to purchase an initial volume of approximately 0.9M tons per annum, or mtpa, beginning in July 2022, which increases to 1.8 mtpa. The SPA has a term of approximately 17.5 years and Sinochem Group will purchase the LNG volumes on a free-on-board basis. The purchase price for LNG under the SPA is indexed to the Henry Hub price, plus a fixed liquefaction fee. The Corpus Christi Stage 3 project is being developed to include up to seven midscale liquefaction trains with a total expected nominal production capacity of over 10 mtpa. It has received all necessary regulatory approvals.

08:08 EDT Mullen Automotive commences trading on NASDAQ - Mullen Automotive announces that the Company begins trading today on the Nasdaq Stock Market under new stock ticker symbol "MULN." "Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq capital markets," says David Michery, CEO and chairman of Mullen Automotive. "Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen and I am proud to lead us into the future."

08:06 EDT ShockWave Medical announce one-year results of coronary IVL - Shockwave Medical unveiled new data confirming the safety and effectiveness of coronary Intravascular Lithotripsy, IVL, out to one year, a new gender analysis that found similar outcomes between men and women, and an OCT analysis that found consistent acute performance in eccentric, concentric and nodular calcified lesions. The data from the Disrupt CAD clinical program were presented in several sessions at the 32nd Transcatheter Cardiovascular Therapeutics annual scientific symposium of the Cardiovascular Research Foundation, in Orlando, Florida. First One-Year Outcomes Find Durability of Excellent Procedural Results: The first one-year outcomes from the prospective, multicenter, single-arm, global investigational device exemption Disrupt CAD III study demonstrated low rates of major adverse cardiovascular events and target lesion failure. The MACE results were primarily driven by the rate of non-Q wave myocardial infarction. The MACE rate included low rates of cardiac death, myocardial infarction, and target vessel revascularization one year after the index procedure. OCT Analysis Finds Similar MSA and Stent expansion Across Calcium Morphologies: A pooled analysis of 262 patients enrolled in OCT sub-studies from Disrupt CAD I, II, III, & IV confirmed that coronary IVL achieved excellent MSA and stent expansion consistently in lesions with both eccentric and concentric calcium. MSA and SE at the maximum site of calcification were similar across the four calcium arc quartiles analyzed. In a separate analysis of calcific nodules, coronary IVL was found to have a notable acute effect on calcific nodules, which were identified in 22 percent of cases, either by flattening or fracturing the nodule, resulting in consistent MSA and SE in lesions with calcified nodules or those without. Coronary IVL Found Equally Safe and Effective in Men and Women: A pooled analysis of the Disrupt CAD I, II, III, & IV studies showed IVL was equally safe and effective in men and women, unlike previous findings with atherectomy. The analysis of 628 patients stratified outcomes by sex. Women in the analysis, who accounted for 23 percent of total patients, were older and more likely to have hyperlipidemia, renal insufficiency and prior myocardial infarction. Despite more frequent comorbidities and smaller vessel size in women, the primary safety endpoint of 30-day MACE for women and men was similar. The primary effectiveness endpoint of procedural success for women and men was also similar.

08:03 EDT Goodyear Tire sees $250M benefit in run-rate synergies by mid-2023 from Cooper - On June 7, Goodyear completed its announced Cooper Tire transaction. The company's third quarter and year-to-date results incorporate the operating results of Cooper Tire since June 7. Cooper Tire sales during these periods totaled $907 million and $1.2 billion, respectively. Inventory and other assets of Cooper Tire were recorded based on their fair market value on June 7 and the cost of goods sold of tires sold after that date reflect the "step-up" to fair market value. Merger-adjusted segment operating income excludes the impact of this "step-up" and certain other costs triggered by the combination, which totaled $127 million for the first nine months of 2021, including $77 million in the third quarter. The company continues to expect to deliver significant, immediate and long-term financial benefits as a result of the business combination. The company now anticipates a benefit of $250 million in run-rate synergies by mid-2023, which has been increased from an initial forecast of $165 million. The company expects to realize approximately $20 million of these savings in 2021.The company's estimates relating to other benefits of the transaction remain unchanged. The combination is expected to generate net present value of $450 million or more by utilizing Goodyear's available U.S. tax attributes. These tax attributes are expected to reduce the company's cash tax payments, positioning it to generate additional free cash flow. The company also continues to expect $250 million in one-time working capital benefits.

08:00 EDT Novo Nordisk announces Golden Eagle Mill re-started, processing resumes - Novo Resources announces operations have resumed at its Golden Eagle processing facility. As announced on November 1, 2021, the Golden Eagle Mill underwent maintenance for approximately seven days while the Company repaired its main crushing unit after encountering additional wear during routine scheduled maintenance. Crusher repairs are now complete, and the Golden Eagle Mill was re-started today as a result. In addition, the Company advises that the first phase of a raise to its tailings storage facility is complete and the requisite operating licence has been issued by the Western Australian Department of Water and Environmental Regulation. This phase will provide approximately 12 months of processing capacity. Completion of the second phase is scheduled for early 2022.

07:56 EDT Repligen releases inaugural sustainability report - Repligen released its inaugural sustainability report. Repligen's 2020 Sustainability Report provides an overview of the Company's environmental, social and governance performance in 2020 and into 2021, and provides disclosures aligned to three key reporting frameworks; the Value Reporting Foundation's SASB Medical Equipment and Supplies Standard, the Global Reporting Initiative Standards Core option, and the United Nations Sustainable Development Goals as informed by the Company's materiality assessment. As a participant of the United Nations Global Compact since July 2020, this report also serves to fulfill Repligen's first Communication on Progress commitment. Tony Hunt, President and CEO of Repligen said, "The release of our first sustainability report is an important achievement for the Company and sets a strong foundation for future progress. It underscores our multi-stakeholder approach to ESG, and it is our hope that its contents demonstrate our strong commitment to corporate responsibility and transparency, and our ambition as we increasingly embed sustainability into our daily business decisions and operations."

07:54 EDT Ree Automotive nominates American Axle to supply EDUs - Ree Automotive (REE) announced the nomination of American Axle (AXL) to supply REE with its electric drive units, or EDU. AAM's 3-in-1 electric drive technology - which places the electric motor, gearbox and inverter into a single package - will be integrated into REEcorner technology. The electric drive units will be developed at AAM's Advanced Technology and Development Center in Detroit with delivery of prototypes planned by the end of 2021 with full volume production expected by 2024. The initial integration will be for prototype builds for a U.S.-based delivery van program.

07:49 EDT American Axle selected by Ree Automotive for electric drive technology - American Axle (AXL) has secured an agreement with e-mobility leader REE Automotive (REE) to supply high-performance electric drive units in a modular platform that can support multiple customer vehicle programs. Earlier this year, AAM and REE announced plans to jointly develop a new electric propulsion system that incorporates AAM's EDU into REE's highly modular and disruptive REEcorner technology that enables a fully flat EV chassis for multiple commercial vehicle applications. The electric drive units will be developed at AAM's Advanced Technology and Development Center in Detroit with delivery of prototypes planned by the end of 2021 and full-volume production expected by 2024.

07:46 EDT Telus raises quarterly dividend to C$0.3274 per share

07:39 EDT NFI's New Flyer of America awarded contract from California's SunLine Transit - NFI Group announced that NFI subsidiary New Flyer of America has been awarded a zero-emission contract from California's SunLine Transit Agency for five forty-foot fuel cell-electric Xcelsior CHARGE H2 heavy-duty transit buses. The purchase follows SunLine's previous 2020 order for five Xcelsior CHARGE H2 buses and brings SunLine's total zero-emission fleet to 26 fuel cell-electric vehicles. This hydrogen bus order, and SunLine's previous 2020 zero-emission order, are supported by Federal Transit Administration funds. The Xcelsior CHARGE H2 is a battery-electric vehicle using compressed hydrogen as an energy source and range extender, requiring 6-20 minutes to refuel. Fuel cell-electric technology is fully zero-emission and an innovative way to obtain extended-range operation similar to existing transit vehicles.

07:35 EDT MannKind presents data at 21st Annual Diabetes Technology Meeting - MannKind will present data at the 21st Annual Diabetes Technology Meeting. The data is currently available to meeting attendees and will be presented in an oral session November 11 by Dr. Kevin Kaiserman, Vice President of Medical Affairs and Safety of MannKind. This feasibility study demonstrated that a TI dose - approximately double the estimated mealtime SC injection dose -provided significant reductions in PPGE without severe hypoglycemia. The maximum mean postprandial glucose decreased from 234 to 186 mg/dL and significant reductions in PPGE were observed from 45 to 120 minutes. "MannKind aspires to be a leader in mealtime control as this is a critical need within the diabetes community," said Dr. Kaiserman. "The focus of this feasibility study is to optimize the dose of TI to significantly reduce post-prandial glucose excursions without any severe hypoglycemia." Twenty adult participants with T1D or T2D who were on a stable regimen of basal-bolus insulin therapy were enrolled in this feasibility study. Each subject received an initial dose of TI based on the conversion chart in the current U.S. package insert.

07:34 EDT Deciphera Pharmaceuticals trading resumes

07:34 EDT Dominion affirms long-term earnings, dividend growth guidance

07:30 EDT Groupon, Square announce partnership for merchants to promote their business - Groupon (GRPN) and Square (SQ) announced a partnership designed to make it easy for local merchants to leverage Square's App Marketplace to create marketing campaigns on Groupon to promote their businesses. The integration will also allow Square's Beauty and Wellness and Things to Do merchants to leverage the booking capabilities of Square Appointments for any Groupon campaigns they create, making the customer journey from purchase to booking to redemption more seamless. The ability to connect directly with Groupon via Square is now available to all Square merchants in the United States.

07:28 EDT Deciphera announces INTRIGUE study misses primary endpoint - Deciphera announced top-line results from the INTRIGUE Phase 3 clinical study of Qinlock in patients with gastrointestinal stromal tumor, or GIST, previously treated with imatinib. The study did not meet the primary endpoint of improved progression-free survival, or PFS, compared with the standard of care sunitinib. The study did not achieve the primary efficacy endpoint of progression-free survival as determined by independent radiologic review using modified Response Evaluation Criteria in Solid Tumors, or RECIST. The statistical analysis plan included a hierarchical testing sequence that included testing patients with a KIT exon 11 primary mutation and then in the all patient intent-to-treat population. In patients with a KIT exon 11 primary mutation, Qinlock demonstrated a median PFS of 8.3 months compared to 7 months for the sunitinib arm. Although not formally tested due to the rules of the hierarchical testing sequence, in the AP population Qinlock demonstrated a mPFS of 8.0 months compared to 8.3 months for the sunitinib arm.

07:21 EDT Casi Pharmaceuticals partner to present positive clinical data on BI-1206 - Casi Pharmaceuticals' partner BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced additional positive interim top-line data from its novel anti-FcgammaRIIB antibody BI-1206. The data update comes from the company's Phase 1/2a clinical trial of BI-1206 in combination with rituximab treating patients with indolent relapsed or refractory B-cell non-Hodgkin's lymphoma. BI-1206, in combination with rituximab, demonstrated an objective response rate of 50%, with three complete responses and three partial responses seen in twelve patients evaluated for therapeutic benefit. The treatment stabilized the disease in one additional patient, giving a disease control rate of 58%, 7 out of 12 patients. The complete responses also appear to be long-lasting, sustaining beyond 18 and 24 months in two patients completing the study. BI-1206 showed a good safety profile. BI-1206 is BioInvent's lead drug candidate and is currently being investigated in two Phase 1/2 trials for non-Hodgkin's lymphoma and in solid tumors.

07:19 EDT Farmland Partners provides update on solar projects in Illinois - Farmland Partners announced updates on the development of solar projects on certain of its farms in Illinois. The first project consists of approximately 432 acres, with power production tentatively slated to commence as early as December 2021. The second solar project is comprised of approximately 1,542 acres, for which the company received notice of construction commencement on November 1, 2021. The average agricultural rent for the two farms is approximately $245 per acre. Once the farms are fully developed as solar projects, the average rent is expected to be $570 per acre. A third 52-acre solar project in North Carolina continues to produce revenue of approximately $600 per acre in excess of the farm rent that would have been generated solely from agricultural uses. Portfolio-wide, the company has approximately 20,000 acres of solar and wind projects under option or at various stages of development and planning.

07:14 EDT Patriot One secures $2M from Raytheon Technologies - Patriot One Technologies (PTOTF) announces a $2M USD Industrial and Technological Benefits transaction through a partnership with defense contractor Raytheon Technologies Corporation (RTX). The funds will be used for the continued innovation and development of Patriot One's AI-powered Platform for threat and weapon detection. "We are delighted that Raytheon has selected us for their continued support and their strategic partnership in the development of our threat detection and patron screening solutions," expressed Peter Evans, Chief Executive Officer of Patriot One. "This support again signals the importance of our vision to become one of the foremost proponents and providers of innovative commercial threat countermeasures for community safety."

07:09 EDT Calithera Biosciences promotes Emil Kuriakose to Chief Medical Officer - Calithera Biosciences announces the promotion of current vice president and head of clinical development, Dr. Emil T. Kuriakose, to chief medical officer, CMO. Dr. Kuriakose will succeed Dr. Keith Orford, who has been appointed to Calithera's board of directors. During his time at Calithera, Dr. Kuriakose has overseen the advancement of the company's clinical development programs, including the arginase inhibitor programs in oncology and cystic fibrosis, as well as multiple telaglenastat trials.

07:08 EDT Calithera Biosciences announces decision to discontinue KEAPSAKE trial - Calithera Biosciences announced the decision to terminate its phase 2 KEAPSAKE clinical trial based on a lack of clinical benefit observed in patients treated with telaglenastat in an interim analysis. "We are disappointed in this outcome for the KEAPSAKE trial, but it was a well-run study with an interim analysis that gave us an answer to an important clinical question. We also want to express our sincere gratitude to the patients who participated in the trial and their families, as well as the physicians who served as investigators for the trial and their site staff," said Susan Molineaux, PhD, chief executive officer of Calithera. "We remain committed to patients with difficult-to-treat cancers and will continue to advance our investigational targeted therapies for biomarker-specific patient populations. Our near-term clinical development plans include leveraging our clinical and biomarker expertise in the KEAP1/NRF2 pathway in the development of our mTORC1/2 inhibitor sapanisertib in squamous non-small cell lung cancer, as well as advancing the development of our SYK inhibitor mivavotinib in specific biomarker-defined populations of diffuse large B-cell lymphoma. In addition, we are continuing the development of our arginase inhibitor CB-280 for the treatment of cystic fibrosis."

07:05 EDT TC Energy announces $0.8B WR Project - TC Energy announced that it has approved its WR Project, a set of projects anticipated to constitute a total capital investment of approximately $0.8B. The Project is designed to increase base system reliability and expand an existing portion of the ANR Pipeline system to serve markets in the midwestern U.S., while lowering emissions by approximately 30,000 metric tons CO2e per year. "The electrification of horsepower for the Project is expected to result in approximately 43 percent reduction in carbon dioxide equivalent emissions at the source with full utilization of the electric drive units - consistent with TC Energy's approach to optimize our existing footprint with more sustainable infrastructure while improving reliability and organically growing our business along our existing corridor," said Francois Poirier, TC Energy's President and Chief Executive Officer. The WR Project is expected to be brought in service in the fourth quarter of 2025.

06:54 EDT Huntsman announces Albemarle agreement to pay $665M arbitration award - Huntsman (HUN) announced that Albemarle (ALB) had agreed to accelerate payment of the award Huntsman received in a recent arbitration case. Under the agreement reached after discussions directly between the two companies' CEOs, Albemarle will pay Huntsman $665M in two equal installments, the first of which will be made before December 3 and the second one before May 2, 2022. Net of legal fees but before taxes, Huntsman will receive $465M in total. After receipt of the second payment, Huntsman will terminate all proceedings relating to the dispute.

06:49 EDT Tegna files cross-complaint against Dish for bad faith conduct - Tegna (TGNA) announced that it has filed a response to DISH's (DISH) baseless complaint to the FCC and, in addition, has filed its own cross-complaint against DISH for its failure to comply with the FCC's good faith rules and its material misrepresentations about the negotiation to the FCC and the public. The company issued the following statement: "As we speak, millions of DISH customers are being deprived of valued local and national news, weather coverage, NFL and college football and top-rated entertainment shows. Instead of working to restore our programming, DISH is abusing the FCC's processes and, more importantly, wasting their customers' time with baseless complaints. Our response and cross-complaint show that it is DISH which has acted in bad faith, not only by obstructing negotiations over many months but also through the distortions it has presented to the public and the FCC. Unfortunately, DISH's behavior is consistent with its track record of obstructive tactics. Last year alone, DISH deprived its customers of more than 230 different channels due to disputes like this one. In addition, the company has a long history of abusing the process by bringing business disputes to regulators and courts. We welcome the FCC's review of DISH's conduct, but our main focus remains on reaching a fair, market-based deal, just as we have with DISH's competitors over the past several years. We yet again call on DISH to engage in serious negotiations with us to retore its subscribers' access to our stations' valued programming. TEGNA continues to encourage DISH subscribers to make their voices heard on this matter and, if DISH continues to deny them access to channels they value, to consider switching to providers that carry those channels."

06:47 EDT Pfizer COVID-19 oral antiviral reduced risk of hospitalization or death by 89% - Pfizer announced its investigational novel COVID-19 oral antiviral candidate, PAXLOVID, significantly reduced hospitalization and death, based on an interim analysis of the Phase 2/3 EPIC-HR randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness. The scheduled interim analysis showed an 89% reduction in risk of COVID-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset; 0.8% of patients who received PAXLOVID were hospitalized through Day 28 following randomization, compared to 7.0% of patients who received placebo and were hospitalized or died. The statistical significance of these results was high. Similar reductions in COVID-19-related hospitalization or death were observed in patients treated within five days of symptom onset; 1.0% of patients who received PAXLOVID were hospitalized through Day 28 following randomization, compared to 6.7% of patients who received a placebo, with high statistical significance. In the overall study population through Day 28, no deaths were reported in patients who received PAXLOVID as compared to 10 deaths in patients who received placebo. At the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration, Pfizer will cease further enrollment into the study due to the overwhelming efficacy demonstrated in these results and plans to submit the data as part of its ongoing rolling submission to the U.S. FDA for Emergency Use Authorization as soon as possible.

06:44 EDT Northern Oil and Gas narrows 2021 production view to 51,750-53,750 Boe/d - Had previously seen 49,500-54,250 Boe/d. Narrows 2021 CapEx view to $215M-$250M from $215M-$260M.

06:23 EDT Occidental Petroleum sees Q4 oil & gas production 1.125-1.155 Mboed - Comments taken from Q3 earnings conference call presentation slides.

06:14 EDT Monmouth Real Estate reaches cooperation agreement with Blackwells Capital - Monmouth Real Estate (MNR) announced that it has reached a cooperation agreement with Blackwells Capital, which owns approximately 4.3% of the company's outstanding common stock. In a separate press release, Monmouth announced that it has entered into a transaction under which Industrial Logistics Properties Trust (ILPT) will acquire Monmouth. "Blackwells recognized early on that the company and its unrivalled portfolio, which we have deliberately built, was well-positioned to generate compelling value for shareholders and all stakeholders. We appreciate that Blackwells has affirmed its support of our strategies, Board and management team and of the strategic review process outcome we announced today," said Michael Landy, President and CEO. Jason Aintabi, Chief Investment Officer of Blackwells said, "Monmouth deserves great credit for choosing decisively to re-initiate a new strategic review process overseen by the full Board of Directors, and explore and solicit a range of alternatives from interested parties, including Blackwells, once the EQC transaction was terminated. This negotiated and unanimously approved all-cash, value-maximizing transaction provides certainty of strong value, and offers a substantial premium, including to prior offers. We believe Monmouth has made the right decision for all shareholders, and as such, we are today standing down from the proxy contest." Blackwells has, among other things, withdrawn its slate of proposed nominees and various shareholder proposals and committed to vote its shares in favor of all of the Board's nominees and in support of all Board-recommended proposals, including in favor of the Transaction. Blackwells will also abide by certain additional standstill, voting and affirmative solicitation commitments and terms.

06:03 EDT Monmouth Real Estate to be acquired by ILPT for $21.00 per share, or $4B - Monmouth Real Estate (MNR) announced that it has entered into a definitive merger agreement with Industrial Logistics Properties Trust (ILPT) under which ILPT will acquire all of the outstanding shares of Monmouth for $21.00 per share in an all-cash transaction valued at approximately $4B including the assumption of debt and the committed acquisition and expansion pipeline. The Transaction has been unanimously approved by Monmouth's Board of Directors. The Transaction price of $21.00 per share represents a 24% premium to the unaffected closing share price of $16.99 on December 18, 2020 and a 36% premium to the 30-day volume weighted average unaffected trading share price of $15.43. The Transaction is expected to close in the first half of 2022, subject to approval by Monmouth's shareholders and the satisfaction of other customary closing conditions. The Transaction is not contingent upon financing. Upon completion of the Transaction, Monmouth's common stock will no longer be listed on the New York Stock Exchange.

05:42 EDT AGBA Acquisition enters business combination agreement with TAG Holdings - AGBA Acquisition announced that it has entered into a business combination agreement with TAG Holdings, a British Virgin Islands diversified financial holding company, and its wholly-owned subsidiaries, TAG International, a British Virgin Islands business company engaged in business-to-business services, TAG Asset Partners, a wholly-owned subsidiary of B2B, OnePlatform International, a wholly owned subsidiary of B2BSub, OnePlatform Holdings, a Hong Kong-headquartered company that engages in business-to-business services through its wholly-owned subsidiaries and TAG Asia Capital, a British Virgin Islands business company which engages in the financial technology sector through its wholly-owned subsidiaries. As part of the transaction, OPH will first become a subsidiary of B2B through a merger with HKSub, following which AGBA will form two wholly-owned subsidiaries which will merge with B2B and Fintech, respectively, with B2B and Fintech as the surviving entities. In consideration of the acquisition merger, AGBA will issue 55M ordinary shares with a deemed price per share of $10.00, as directed by TAG, in its capacity as the sole shareholder of B2B and Fintech. Upon the completion of the business combination, the parties plan for the combined company to be Nasdaq-listed under AGBA's current ticker symbol - AGBA. The post-combination combined company of the platform businesses thereby will become a publicly listed company. Under the terms of the business combination agreement, through the acquisition merger AGBA will acquire all of the issued and outstanding equity securities of each of the platform businesses in consideration for the issuance of 55.5M AGBA ordinary shares, as directed by TAG, in its capacity as the sole shareholder of the B2B and Fintech.

05:15 EDT Huize partners with Huagui Life Insurance to launch 'Da Mai Ding Hai Zhu' - Huize announced that it has partnered with Huagui Life Insurance to launch "Da Mai Ding Hai Zhu", a customized term life insurance product designed to meet the protection needs of the younger generation. There are three key product highlights of "Da Mai Ding Hai Zhu": basic coverage of up to RMB 3M with additional benefits of up to RMB 6M for major traffic accidents and events triggered by natural disasters; care benefits of up to RMB 1.5M for either parent, and special care benefits for death before 45 years old; and increased flexibility in health declaration process, lowering the threshold for consumers with pre-existing conditions.

05:10 EDT Emergent, HHS terminate development and manufacturing contract - Emergent BioSolutions announced a mutual agreement with the U.S. Department of Health and Human Services to terminate the company's 2012 Center for Innovation in Advanced Development and Manufacturing contract to establish a public-private partnership for pandemic preparedness, along with all associated task orders, including the 2020 task order to reserve capacity and expand manufacturing for third-party Covid-19 vaccine and therapeutic candidates. Health and Human Services has stopped paying Emergent under the contract and won't pay the company a remaining $170M under condition allowed by the agreement, a senior U.S. health official told Bloomberg.